Table 2.

Table 2a. Pathologic features and Kaplan-Meier 5-year recurrence-free probabilities by PSA group. Data are represented as frequency (proportion) unless otherwise noted.
Pathologic Features	Pretreatment PSA (ng/ml)
	0–0.5	0.6–1.0	1.1–2.0	2.0–3.0	>3.0
	N=25	N=66	N=176	N=326	N=5537
Pathologic Gleason
<=6	11 (44%)	50 (76%)	98 (56%)	158 (48%)	1881 (34%)
7	9 (36%)	14 (21%)	67 (38%)	154 (47%)	3182 (57%)
>=8	3 (12%)	2 (3%)	6 (3%)	11 (3%)	416 (8%)
Unknown	2 (8%)	0 (0%)	5 (3%)	3 (1%)	58 (1%)
Extracapsular Extension
No	16 (64%)	59 (89%)	153 (87%)	258 (79%)	3896 (70%)
Yes	8 (32%)	7 (11%)	20 (11%)	60 (18%)	1593 (29%)
Unknown	1 (4%)	0 (0%)	3 (2%)	8 (2%)	48 (1%)
Seminal Vesicle Invasion
No	22 (88%)	65 (98%)	171 (97%)	313 (96%)	5130 (93%)
Yes	2 (8%)	1 (2%)	3 (2%)	9 (3%)	377 (7%)
Unknown	1 (4%)	0 (0%)	2 (1%)	4 (1%)	30 (1%)
Lymph Node Involvement
No	24 (96%)	64 (97%)	173 (98%)	323 (99%)	5346 (97%)
Yes	1 (4%)	2 (3%)	3 (2%)	3 (1%)	191 (3%)
Non-Organ Confined
No	16 (64%)	58 (88%)	153 (87%)	255 (78%)	3801 (69%)
Yes	8 (32%)	8 (12%)	20 (11%)	62 (19%)	1675 (30%)
Unknown	1 (4%)	0 (0%)	3 (2%)	9 (3%)	61 (1%)
5-Year Recurrence-free Probability (95% C.I.)	76% (24%, 95%)	100%	92% (82%, 96%)	97% (93%, 99%)	85% (83%, 86%)

Table 2b. Patients with low clinical stage (T1). Pathologic features and Kaplan-Meier 5-year recurrence-free probabilities by PSA group. Data are represented as frequency (proportion) unless otherwise noted.
Pathologic Features	Pretreatment PSA (ng/ml)
	0–0.5	0.6–1.0	1.1–2.0	2.0–3.0	>3.0
	N=8	N=26	N=65	N=183	N=3800
Pathologic Gleason
<=6	4 (50%)	21 (81%)	41 (63%)	103 (56%)	1467 (39%)
7	4 (50%)	5 (19%)	18 (28%)	75 (41%)	2114 (56%)
>=8	0 (0%)	0 (0%)	3 (5%)	3 (2%)	191 (5%)
Unknown	0 (0%)	0 (0%)	3 (5%)	2 (1%)	28 (1%)
Extracapsular Extension
No	4 (50%)	26 (100%)	57 (88%)	158 (86%)	2923 (77%)
Yes	4 (50%)	0 (0%)	6 (9%)	19 (10%)	845 (22%)
Unknown	0 (0%)	0 (0%)	2 (3%)	6 (3%)	32 (1%)
Seminal Vesicle Invasion
No	8 (100%)	26 (100%)	63 (97%)	178 (97%)	3615 (95%)
Yes	0 (0%)	0 (0%)	1 (2%)	3 (2%)	165 (4%)
Unknown	0 (0%)	0 (0%)	1 (2%)	2 (1%)	20 (1%)
Lymph Node Involvement
No	8 (100%)	25 (96%)	64 (98%)	182 (99%)	3740 (98%)
Yes	0 (0%)	1 (4%)	1 (2%)	1 (1%)	60 (2%)
Non-Organ Confined
No	4 (50%)	25 (96%)	57 (88%)	157 (86%)	2877 (76%)
Yes	4 (50%)	1 (4%)	6 (9%)	20 (11%)	882 (23%)
Unknown	0 (0%)	0 (0%)	2 (3%)	6 (3%)	41 (1%)
5-Year Recurrence-Free Probability (95% C.I.)	100%	100%	86% (61%, 96%)	97% (89%, 99%)	89% (88%, 91%)

Table 2c. Patients with high clinical stage (T2 or higher). Pathologic features and Kaplan-Meier 5-year recurrence-free probabilities by PSA group. Data are represented as frequency (proportion) unless otherwise noted.
Pathologic features	Pretreatment PSA (ng/ml)
	0–0.5	0.6–1.0	1.1–2.0	2.0–3.0	>3.0
	N=17	N=40	N=111	N=143	N=1737
Pathologic Gleason
<=6	7 (41%)	29 (73%)	57 (51%)	55 (38%)	414 (24%)
7	5 (29%)	9 (23%)	49 (44%)	79 (55%)	1068 (61%)
>=8	3 (18%)	2 (5%)	3 (3%)	8 (6%)	225 (13%)
Unknown	2 (12%)	0 (0%)	2 (2%)	1 (1%)	30 (2%)
Extracapsular Extension
No	12 (71%)	33 (83%)	96 (86%)	100 (70%)	973 (56%)
Yes	4 (24%)	7 (18%)	14 (13%)	41 (29%)	748 (43%)
Unknown	1 (6%)	0 (0%)	1 (1%)	2 (1%)	16 (1%)
Seminal Vesicle Invasion
No	14 (82%)	39 (98%)	108 (97%)	135 (94%)	1515 (87%)
Yes	2 (12%)	1 (3%)	2 (2%)	6 (4%)	212 (12%)
Unknown	1 (6%)	0 (0%)	1 (1%)	2 (1%)	10 (1%)
Lymph Node Involvement
No	16 (94%)	39 (98%)	109 (98%)	141 (99%)	1606 (92%)
Yes	1 (6%)	1 (3%)	2 (2%)	2 (1%)	131 (8%)
Non-Organ Confined
No	12 (71%)	33 (83%)	96 (86%)	98 (69%)	924 (53%)
Yes	4 (24%)	7 (18%)	14 (13%)	42 (29%)	793 (46%)
Unknown	1 (6%)	0 (0%)	1 (1%)	3 (2%)	20 (1%)
5-Year Recurrence-Free Probability (95% C.I.)	75% (13%, 96%)	100%	94% (81%, 98%)	97% (92%, 99%)	77% (74%, 79%)